Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Item
http://www.wikidata.org/entity/Q43695561
Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available.Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolyticCost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancerFive-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols.Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Cost-effectiveness of cetuximab for colorectal cancer.Targeted therapy in metastatic colon cancer.Ephrin b2 receptor and microsatellite status in lymph node-positive colon cancer survival.How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer
P2860

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Item
http://www.wikidata.org/entity/Q43695561
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Cost-effectiveness of targeted ...... the liver in a German setting.
@en
Cost-effectiveness of targeted ...... the liver in a German setting.
@nl
type
label
Cost-effectiveness of targeted ...... the liver in a German setting.
@en
Cost-effectiveness of targeted ...... the liver in a German setting.
@nl
prefLabel
Cost-effectiveness of targeted ...... the liver in a German setting.
@en
Cost-effectiveness of targeted ...... the liver in a German setting.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Cost-effectiveness of targeted ...... the liver in a German setting.
@en
P2093
P304
P31
P356
10.1016/J.CLINTHERA.2011.04.010
P433
P478
P50
P577
P698
P921